Being Well-Informed About Statin is Associated with Continuous Adherence and Reaching Targets
- 1 December 2005
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 19 (6) , 437-440
- https://doi.org/10.1007/s10557-005-5202-5
Abstract
Background: Statins are life saving drugs in cardiovascular practice. However, they still are underprescribed in many situations despite their well-established benefits. Adherence may be improved by increased comprehension of the patients. Methods: Patients enrolled into a previous survey were randomized into two groups as those, who were informed comprehensively (Group 1) and those not (Group 2). 202 patients, all of whom were on secondary prevention, were contacted after median 15 months of follow up and evaluated whether they continued the statins, and reached targets. Results: 102 out of 202 patients were those enrolled into Group 1, and 100 of them were those enrolled into Group 2. In Group 1, 62.7% of patients were on continuous statin therapy during period betweeen initial and secondary contact, whereas, only 46% of patients in Group 2 were on continuous statin therapy (p = 0.017). Being well-informed about statin increased the likelihood of being on continuous statin therapy after median of 15 months by 1.977 folds. Concerning targets, 64.7% of those in Group 1 reached the targets, whereas, 43% of those in Group 2 reached the targets (p = 0.002). Being well-informed about statin increased the likelihood of having suggested targets by ATP III after median of 15 months by 2.430 folds. Conclusion: Providing patients with comprehensive knowledge about statins, even in patients, who were already on statin therapy, seems not only to improve adherence but also increase the percentage of those reaching targets.Keywords
This publication has 14 references indexed in Scilit:
- Follow-up lipid tests and physician visits are associated with improved adherence to statin therapyPharmacoEconomics, 2004
- Level of Awareness of on-Treatment Patients About Prescribed StatinsCardiovascular Drugs and Therapy, 2004
- Determinants of non‐compliance with lipid‐lowering therapy in hyperlipidemic patientsPharmacoepidemiology and Drug Safety, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A ReappraisalDrug Safety, 1996
- Changing Physician PerformanceJAMA, 1995
- HMG CoA reductase inhibitorsCurrent Opinion in Lipidology, 1994
- Effects of computer generated reminder charts on patients' compliance with drug regimens.BMJ, 1993